Acquisition by Odonnell-tormey Jill of 112000 shares of Coherus BioSciences at 1.76 subject to Rule 16b-3
CHRS Stock | USD 1.22 0.04 3.17% |
Slightly above 53% of Coherus BioSciences' investor base is interested to short. The analysis of the overall investor sentiment regarding Coherus BioSciences suggests that many traders are impartial. Coherus BioSciences' investing sentiment can be driven by a variety of factors including economic data, Coherus BioSciences' earnings reports, geopolitical events, and overall market trends.
Coherus |
Filed transaction by Coherus BioSciences Director. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
Cash Flow Correlation
Coherus BioSciences' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Coherus BioSciences' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Coherus BioSciences Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Coherus BioSciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Coherus BioSciences Fundamental Analysis
We analyze Coherus BioSciences' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Coherus BioSciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Coherus BioSciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash Per Share
Cash Per Share Comparative Analysis
Coherus BioSciences is currently under evaluation in cash per share category among its peers. Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Coherus BioSciences Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Coherus BioSciences stock to make a market-neutral strategy. Peer analysis of Coherus BioSciences could also be used in its relative valuation, which is a method of valuing Coherus BioSciences by comparing valuation metrics with similar companies.
Peers
Coherus BioSciences Related Equities
CTMX | CytomX Therapeutics | 3.92 | ||||
BOLT | Bolt Biotherapeutics | 1.59 | ||||
ASMB | Assembly Biosciences | 1.25 | ||||
ACHL | Achilles Therapeutics | 0.93 | ||||
SPRO | Spero Therapeutics | 0.88 | ||||
NUVB | Nuvation Bio | 0.35 | ||||
NXTC | NextCure | 2.50 | ||||
TIL | Instil Bio | 9.39 |
Additional Tools for Coherus Stock Analysis
When running Coherus BioSciences' price analysis, check to measure Coherus BioSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coherus BioSciences is operating at the current time. Most of Coherus BioSciences' value examination focuses on studying past and present price action to predict the probability of Coherus BioSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coherus BioSciences' price. Additionally, you may evaluate how the addition of Coherus BioSciences to your portfolios can decrease your overall portfolio volatility.